West Pharmaceutical Services Inc【WST】株式ニュース

West Reports First-Quarter 2026 ResultsApril 23, 2026 6:00 AM
PR Newswire (US)

Strong Start to the Year and Raising Full-Year Revenue and EPS guidanceEXTON, Pa., April 23, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a leading provider of innovative, high-quality injectable solutions and services, today announced its financial results for the first quarter of 2026.

First-Quarter Summary (comparisons to prior-year period)Net sales of $844.9 million increased 21.0%; organic growth was 15.3%.Diluted earnings per share ("EPS") of $1.92 increased 56.1%.Adjusted-diluted EPS of $2.13 increased 46.9%.Operating cash flow was $89.9 million. Capital expenditures were $42.7 million. Free cash flow (defined as operating cash flow less capital expenditures) was $47.2 million.The Company repurchased 1.2 million shares for $297.6 million at an average price of $243.57 per share under its share repurchase program that was announced in mid-February 2026.Outlook for Full-Year and Second Quarter 2026Full-year 2026 net sales guidance increased to a range of $3.295 billion to $3.350 billion, up from $3.215 billion to $3.275 billion and full-year 2026 adjusted-diluted EPS guidance increased to a range of $8.40 to $8.75, up from $7.85 to $8.20.Second quarter 2026 net sales are expected to be in the range of $830 million to $850 million, up 8.3% to 10.9% reported and up 7.0% to 9.6% organic.Eric M. Green, President, Chief Executive Officer and Chair of the Board, commented: "I am pleased to report a very strong start to the year with revenues and adjusted EPS exceeding expectations. Our revenues grew 15% organically, driven by our High Value Products Components business with double-digit growth in both GLP-1 and non-GLP-1 revenues. The better-than-expected performance can be attributed to continued market demand and the team's outstanding efforts in ramping up production, especially in Europe. As a result of these excellent first quarter results and expected continued momentum in our business, we are increasing our full-year 2026 guidance."Proprietary Products Segment
Net sales of $694.3 million grew by 23.3% and increased 17.5% on an organic basis.High-Value Product ("HVP") Components net sales of $409.3 million increased 29.6% and rose 22.6% on an organic basis driven by strength in Westar® and NovaPure® products. HVP Components accounted for 48% of total company net sales in the quarter.HVP Delivery Devices net sales of $123.6 million increased by 29.0%, and were up 27.5% on an organic basis, driven by increased sales of self-injection device platforms and Daikyo Crystal Zenith®. HVP Delivery Devices accounted for 15% of total company net sales in the quarter.Standard Products net sales of $161.4 million increased by 6.7% and rose 0.5% on an organic basis. Standard Products accounted for 19% of total company net sales this quarter.West Vantage Segment
Effective in the first quarter of 2026, the Company renamed its "Contract-Manufactured Products" reportable segment to "West Vantage™" to better align with its current strategic focus and offerings. This change in name does not affect the composition of the reportable segment, nor does it impact previously reported segment financial information. Net sales of $150.6 million increased by 11.6% and rose 6.2% on an organic basis. Segment performance was driven by an increase in sales of self-injection devices for obesity and diabetes. West Vantage accounted for 18% of total company net sales in the quarter.Full-Year 2026 Financial Guidance The Company is increasing its full-year 2026 net sales guidance range to $3.295 billion to $3.350 billion, which continues to assume a mid-year close for the sale of SmartDose® 3.5mL to Abbvie, up from $3.215 billion to $3.275 billion.Reported net sales growth is now anticipated to be in the range of 7.2% to 9.0%, and organic net sales growth is expected to be in the range of 7% to 9%.Net sales guidance includes an estimated full-year 2026 benefit of approximately 2 percentage points based on current foreign currency exchange rates.SmartDose® 3.5mL generated $55 million in revenues in the second half of 2025. These revenues are excluded to calculate our full-year 2026 organic revenue growth guidance.The Company is increasing its full-year 2026 adjusted-diluted EPS guidance range to $8.40 to $8.75, up from the previous range of $7.85 to $8.20.Capital spending guidance is unchanged from a range of $250 million to $275 million.Second-Quarter 2026 Financial Guidance The Company is introducing its second-quarter 2026 net sales guidance range of $830 million to $850 million.Reported net sales growth anticipated to be in the range of 8.3% to 10.9%, organic net sales growth is expected to be in the range of 7.0% to 9.6%.Net sales guidance includes an estimated second-quarter 2026 benefit of approximately 1.3 percentage points based on current foreign currency exchange rates.The Company is introducing its second-quarter 2026 adjusted-diluted EPS guidance range of $2.05 to $2.12, up 11.4% to 15.2%.First-Quarter 2026 Conference Call
Management will host a conference call at 8 a.m. EDT today. The live webcast can be accessed in the "Investors" section of the Company's website and by clicking here.To participate in the Q&A portion of the conference call, please register in advance by clicking here.Registered telephone participants will receive the dial-in number along with a unique PIN number that will enable them to ask questions on the call.An accompanying slide presentation will be posted in the "Investors" section of the Company's website.A replay of the webcast will be available on the Company's website for approximately 90 days after the event.About West
West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug developers, West helps ensure the safe, effective containment and delivery of life-saving and life-enhancing medicines for patients. With over 10,000 team members across 50 sites including 26 manufacturing facilities worldwide, West helps support our customers by delivering over 41 billion components and devices each year. Headquartered in Exton, Pennsylvania, West in its fiscal year 2025 generated $3.07 billion in net sales. West is traded on the New York Stock Exchange (NYSE: WST) and is included in the Standard & Poor's 500 index. For more information, visit www.westpharma.com.All trademarks and registered trademarks used in this release are the property of West Pharmaceutical Services, Inc. or its subsidiaries, in the United States and other jurisdictions, unless otherwise noted.Daikyo®, Daikyo Crystal Zenith® and Daikyo CZ® are registered trademarks of Daikyo Seiko, Ltd. Daikyo Crystal Zenith technologies are licensed from Daikyo Seiko, Ltd.Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the Company's expectations regarding future events, financial guidance and financial or operational performance. Forward-looking statements may be identified by words such as "believe," "expect," "intend," "estimate," "plan," "anticipate," "project," "forecast," "guidance," "target," "may," "will," "continue" and similar expressions.These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. For additional information regarding these risks as well as other risks, uncertainties and factors that could affect our forward-looking statements, please refer to Part I Item 1A, entitled "Risk Factors," of the Company's most recent Annual Report on Form 10-K and any amendments thereto, as well as the Company's most recently filed Quarterly Reports on Form 10-Q and other filings the Company makes with the Securities and Exchange Commission.Forward-looking statements speak only as of the date of this press release. Except as required by law or regulation, West Pharmaceutical Services, Inc. undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.Non-U.S. GAAP Financial Measures
The Company reports its financial results in accordance with U.S. generally accepted accounting principles ("U.S. GAAP"). However, management also uses certain non-U.S. GAAP financial measures in evaluating our results of operations. Management believes that this information provides users with a valuable insight into our overall performance and financial position. As a result, this release contains certain non-GAAP financial measures, including organic net sales, adjusted-diluted EPS and adjusted operating profit. Organic net sales exclude the impact from acquisitions and/or divestitures and translate the current-period reported sales of subsidiaries whose functional currency is other than the U.S. Dollar at the applicable foreign currency exchange rates in effect during the comparable prior-year period. We may also refer to financial results, such as adjusted-diluted EPS and adjusted operating profit, that exclude the effects of unallocated items. The unallocated items are not representative of ongoing operations, and generally include restructuring and related charges, certain asset impairments, and other specifically identified income or expense items. These non-U.S. GAAP financial measures should be viewed in addition to, and not as an alternative for, the Company's results prepared in accordance with U.S. GAAP. A reconciliation of these non-U.S. GAAP measures to the comparable U.S. GAAP financial measures is included in the accompanying tables.WEST PHARMACEUTICAL SERVICES, INC.CONSOLIDATED STATEMENTS OF INCOME(UNAUDITED)(in millions, except per share data)

Three Months Ended
March 31,
2026
2025Net sales$         844.9
100 %
$         698.0
100 %Cost of goods and services sold548.5
65
466.1
67Gross profit296.4
35
231.9
33Research and development15.8
2
16.3
2Selling, general and administrative expenses99.5
12
88.0
13Other expense (income), net4.0
—
20.6
3Operating profit177.1
21
107.0
15Interest (income) expense, net(3.2)
—
(3.7)
(1)Other nonoperating expense (income)0.2
—
0.2
—Income before income taxes and equity in
net income of affiliated companies180.1
21
110.5
16Income tax expense44.7
5
24.1
3Equity in net income of affiliated companies(3.4)
—
(3.4)
—Net income$         138.8
16 %
$           89.8
13 %

Net income per share:

Basic$           1.93

$           1.24

Diluted$           1.92

$           1.23

Average common shares outstanding72.0

72.5

Average shares assuming dilution72.4

73.0

WEST PHARMACEUTICAL SERVICESREPORTING SEGMENT INFORMATION(UNAUDITED)(in millions)

Three Months EndedMarch 31,Net Sales:2026
2025Proprietary Products$       694.3
$       563.0West Vantage150.6
135.0Consolidated Total$       844.9
$       698.0

Gross Profit:

Proprietary Products$       273.1
$       210.2West Vantage23.3
21.7Gross Profit$       296.4
$       231.9Gross Profit Margin35.1 %
33.2 %

Operating Profit (Loss):

Proprietary Products$       189.2
$       130.6West Vantage15.6
13.5Stock-based compensation expense(6.6)
(1.3)General corporate costs(21.1)
(35.8)Reported Operating Profit$       177.1
$       107.0Reported Operating Profit Margin21.0 %
15.3 %

Unallocated items3.9
18.0Adjusted Operating Profit$       181.0
$       125.0Adjusted Operating Profit Margin21.4 %
17.9 %WEST PHARMACEUTICAL SERVICESRECONCILIATION OF NON-U.S. GAAP MEASURES (UNAUDITED)Please refer to "Non-U.S. GAAP Financial Measures" for more information(in millions, except per share data)
Reconciliation of Reported and Adjusted Operating Profit, Net Income and Diluted EPS
Three Months ended March 31, 2026Operatingprofit
Incometaxexpense
Netincome
DilutedEPSReported (U.S. GAAP)$177.1
$44.7
$138.8
$1.92Unallocated Items:

Restructuring and other charges (1)1.4
(11.6)
13.0
0.18SmartDose® 3.5mL sale (2)1.9
0.4
1.5
0.02Amortization of acquisition-related intangible assets (3)—
—
0.5
0.01Other0.6
0.2
0.5
—Adjusted (Non-U.S. GAAP)$181.0
$33.7
$154.3
$2.13
Three Months ended March 31, 2025Operatingprofit
Incometaxexpense
Netincome
DilutedEPSReported (U.S. GAAP)$107.0
$24.1
$89.8
$1.23Unallocated items:

Restructuring and other charges (1)17.8
2.0
15.8
0.21Amortization of acquisition-related intangible assets (3)0.2
—
0.6
0.01Adjusted (Non-U.S. GAAP)$125.0
$26.1
$106.2
$1.45(1)During the three months ended March 31, 2026, the Company recorded pre-tax charges of $1.4 million related to our two existing restructuring programs: (i) $0.9 million within other expense (income), related to acceleration of depreciation and lease costs in connection with the Company's January 2025 restructuring plan and (ii) $0.5 million within selling, general and administrative expenses, for professional services relating to our 2024 plan to optimize the legal structure of the Company and its subsidiaries. In addition, we recorded a one-time tax cost of $12.0 million associated with an internal legal entity restructuring which occurred in the first quarter of 2026. During the three months ended March 31, 2025, the Company recorded pre-tax charges of $17.8 million related to our two existing restructuring programs: (i) $16.4 million within other expense (income), related to severance, acceleration of depreciation and lease costs in connection with the Company's January 2025 restructuring plan and (ii) $1.4 million within selling, general and administrative expenses, for professional services relating to our 2024 plan to optimize the legal structure of the Company and its subsidiaries. In addition, we recorded income tax charges of $2.0 million related primarily to withholding tax and capital gains incurred in executing our plan to optimize our legal structure.

(2)During the three months ended March 31, 2026, the Company recorded charges of $1.9 million related to the Company's agreement to sell its SmartDose® 3.5mL On-Body Delivery System and associated facilities to AbbVie. The Company recorded $0.9 million of the charges within other expense (income), related to employee benefit costs in connection with the sale agreement. The Company recorded the remaining $1.0 million within selling, general and administrative expenses, relating to professional services in connection with the sale agreement.

(3)During the three months ended March 31, 2026, and 2025, the Company recorded $0.0 million and $0.2 million, respectively, of amortization expense within selling, general and administrative expenses associated with an intangible asset acquired during the second quarter of 2020. During the three months ended March 31, 2026, and 2025, the Company recorded $0.5 million and $0.4 million, respectively, of amortization expense in association with an acquisition of increased ownership interest in Daikyo.WEST PHARMACEUTICAL SERVICESRECONCILIATION OF NON-U.S. GAAP FINANCIAL MEASURES (UNAUDITED)Please refer to "Non-U.S. GAAP Financial Measures" for more information(in millions, except per share data)
Reconciliation of Reported Net Sales to Organic Net Sales by Segment (4)
Three Months EndedMarch 31,Reported Net Sales (U.S.
GAAP)
Percent
Change
Impact of
CurrencyOrganic Net Sales
Growth Rate (Decline)
(Non-U.S. GAAP) (4)20262025

Proprietary Products$694.3$563.0
23.3 %
5.8 %17.5 %West Vantage150.6135.0
11.6 %
5.4 %6.2 %Total$844.9$698.0
21.0 %
5.7 %15.3 %
Reconciliation of Proprietary Products Segment Organic Net Sales by Product Category (4)
Three Months EndedMarch 31,Reported Net Sales (U.S.
GAAP)
Percent
Change
Impact of
CurrencyOrganic Net Sales
Growth Rate (Decline)
(Non-U.S. GAAP) (4)20262025

HVP Components$409.3$315.9
29.6 %
7.0 %22.6 %HVP Delivery Devices123.695.8
29.0 %
1.5 %27.5 %Standard Products161.4151.3
6.7 %
6.2 %0.5 %Total Proprietary Products$694.3$563.0
23.3 %
5.8 %17.5 %
Reconciliation of Proprietary Products Segment Organic Net Sales by Market Group (4)
Three Months EndedMarch 31,Reported Net Sales (U.S.
GAAP)
Percent
Change
Impact of
CurrencyOrganic Net Sales
Growth Rate (Decline)
(Non-U.S. GAAP) (4)20262025

Biologics$354.5$269.3
31.6 %
5.7 %25.9 %Pharma210.6180.6
16.6 %
6.8 %9.8 %Generics129.2113.1
14.2 %
4.4 %9.8 %Total Proprietary Products$694.3$563.0
23.3 %
5.8 %17.5 %
Reconciliation of Reported Net Sales to Organic Net Sales by Geography (4)
Three Months EndedMarch 31,Reported Net Sales (U.S.
GAAP)
Percent
Change
Impact of
CurrencyOrganic Net Sales
Growth Rate (Decline)
(Non-U.S. GAAP) (4)20262025

Americas$377.3$338.9
11.3 %
0.5 %10.8 %Europe, Middle East, Africa399.4306.9
30.1 %
12.2 %17.9 %Asia Pacific68.252.2
30.7 %
1.4 %29.3 %Total$844.9$698.0
21.0 %
5.7 %15.3 %(4)Organic net sales exclude the impact from acquisitions and/or divestitures and translate the current-period reported sales of subsidiaries whose functional currency is other than the U.S. Dollar at the applicable foreign currency exchange rates in effect during the comparable prior-year period.WEST PHARMACEUTICAL SERVICESRECONCILIATION OF NON-U.S. GAAP FINANCIAL MEASURES (UNAUDITED)Please refer to "Non-U.S. GAAP Financial Measures" for more information(in millions, except per share data)
Reconciliation of Reported-Diluted EPS Guidance to Adjusted-Diluted EPS Guidance

2025 Actual
2026 Guidance
% ChangeReported-diluted EPS (U.S. GAAP)$6.79
$8.15 to $8.50
20.0% to 25.2%Restructuring and other charges0.31
0.21

SmartDose® 3.5mL sale0.09
0.02

Cost-method investment activity0.06
—

Amortization of acquisition-related intangible assets0.03
0.02

Other0.01
—

Adjusted-diluted EPS (Non-U.S. GAAP)$7.29
$8.40 to $8.75
15.2% to 20.0%WEST PHARMACEUTICAL SERVICESCONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)
(in millions, except per share data)March 31,
2026
December 31,
2025ASSETS

Current assets:

Cash and cash equivalents$         521.4
$         791.3Accounts receivable, net685.6
574.4Inventories452.6
443.9Other current assets167.2
168.6Total current assets1,826.8
1,978.2Property, plant and equipment3,223.0
3,223.4Less: accumulated depreciation and amortization1,520.8
1,497.0Property, plant and equipment, net1,702.2
1,726.4Operating lease right-of-use assets110.2
117.0Investments in affiliated companies209.2
212.3Goodwill109.2
109.9Intangible assets, net7.0
7.7Deferred income taxes63.9
38.4Other noncurrent assets81.3
80.1Total Assets$       4,109.8
$       4,270.0

LIABILITIES AND EQUITY

Current liabilities:

Accounts payable$ 252.3
$ 253.7Accrued salaries, wages and benefits72.6
135.9Income taxes payable78.9
28.1Operating lease liabilities21.4
22.7Accrued commissions, rebates and royalties46.6
39.2Other current liabilities202.2
175.3Total current liabilities674.0
654.9Long-term debt202.8
202.8Deferred income taxes22.7
23.0Pension and other postretirement benefits28.5
29.0Operating lease liabilities92.0
95.6Deferred compensation benefits11.8
13.5Other long-term liabilities87.6
75.2Total Liabilities1,119.4
1,094.0

Equity:

Preferred stock, 3.0 million shares authorized; 0 shares issued and outstanding—
—Common stock, par value $0.25 per share; 200.0 million shares authorized; shares
issued: March 31, 2026 - 75.3 million, December 31, 2025 - 75.3 million; shares
outstanding: March 31, 2026 - 70.9 million, December 31, 2025 - 72.0 million18.8
18.8Capital in excess of par value—
—Retained earnings4,475.9
4,374.9Accumulated other comprehensive loss(125.2)
(105.5)Treasury stock, at cost (March 31, 2026 - 4.4 million shares, December 31, 2025 -
3.3 million shares)(1,379.1)
(1,112.2)Total Equity2,990.4
3,176.0Total Liabilities and Equity$       4,109.8
$       4,270.0WEST PHARMACEUTICAL SERVICESCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)(in millions)

Three Months Ended
March 31,
2026
2025Cash flows from operating activities:

Net income$         138.8
$ 89.8Adjustments to reconcile net income to net cash provided by operating
activities:

Depreciation44.6
39.1Amortization0.6
0.9Stock-based compensation6.6
1.3Non-cash restructuring charges0.9
0.8Asset impairments0.3
0.3Other non-cash items, net1.0
(2.9)Changes in assets and liabilities(102.9)
0.1Net cash provided by operating activities89.9
129.4

Cash flows from investing activities:

Capital expenditures(42.7)
(71.3)Net cash used in investing activities(42.7)
(71.3)

Cash flows from financing activities:

Principal repayments on finance leases(0.3)
(0.2)Dividend payments(15.8)
(15.2)Proceeds from stock-based compensation awards5.5
2.5Employee stock purchase plan contributions2.0
1.9Shares purchased under share repurchase programs(297.6)
(133.5)Shares repurchased for employee tax withholdings(2.5)
(2.5)Net cash used in financing activities(308.7)
(147.0)Effect of exchange rates on cash(8.4)
8.5Net decrease in cash and cash equivalents(269.9)
(80.4)

Cash, including cash equivalents at beginning of period791.3
484.6Cash, including cash equivalents at end of period$         521.4
$         404.2

Supplemental cash flow information:

    Accrued capital expenditures$ 26.1
$ 37.5

View original content to download multimedia:https://www.prnewswire.com/news-releases/west-reports-first-quarter-2026-results-302751100.htmlSOURCE West Pharmaceutical Services, Inc.

Original: West Reports First-Quarter 2026 Results

West Reports Fourth-Quarter and Full-Year 2025 ResultsFebruary 12, 2026 6:00 AM
PR Newswire (US)

– Strong 4Q results, driven by double-digit organic revenue growth in HVP Components –– Introduces Fiscal 2026 Financial Guidance –EXTON, Pa., Feb. 12, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a leading provider of innovative, high-quality injectable solutions and services, today reported its financial results for the fourth quarter and full year 2025.

Fourth-Quarter and Full-Year 2025 Summary (comparisons to prior-year period)Fourth-quarter net sales of $805.0 million increased 7.5%; organic growth was 3.3%.Fourth-quarter diluted earnings per share (EPS) of $1.82 increased 2.2%.Fourth-quarter Adjusted-diluted EPS of $2.04 increased 12.1%.Full-year net sales of $3.074 billion increased 6.3%; organic growth was 4.3%.Full-year Diluted EPS of $6.79 increased 1.5%.Full-year Adjusted-diluted EPS of $7.29 increased 8.0%.Operating cash flow was $754.8 million, an increase of 15.5%. Capital expenditures were $285.9 million. Free cash flow (defined as operating cash flow less capital expenditures) was $468.9 million, an increase of 69.6%.During 2025, the Company repurchased 552,593 shares for $134.0 million at an average share price of $242.55 under its share repurchase programs."Our strong finish to 2025 was a result of the team's relentless execution of our growth strategy," said Eric M. Green, West's President, Chief Executive Officer and Chair of the Board. "Our performance in the quarter was led by our High-Value Product Components business in our Proprietary Products Segment, enabling us to deliver double-digit adjusted earnings per share growth. We expect positive momentum to continue in 2026, which will be a key year of execution and operational excellence to drive sustainable growth and create value for our patients, customers and shareholders."Proprietary Products Segment
Fourth-quarter net sales of $661.8 million grew by 7.8% and increased 3.6% on an organic basis.High-Value Product ("HVP") Components net sales of $389.8 million increased 20.3% and grew 15.1% on an organic basis driven by strength in Westar® and Envision® products. HVP Components accounted for 48% of total company net sales in the quarter.HVP Delivery Devices net sales of $110.4 million decreased by 16.9%, and were down 18.1% on an organic basis, driven by the previously disclosed non-recurring incentive fee of $25 million earned in the fourth quarter of 2024. HVP Delivery Devices accounted for 14% of total company net sales in the quarter.Standard Products net sales of $161.6 million increased by 3.0%, but declined 1.7% on an organic basis. Standard Products accounted for 20% of total company net sales this quarter.Contract-Manufactured Products Segment
Fourth-quarter 2025 net sales increased by 6.2% to $143.2 million, while organic net sales grew 1.9%. Segment performance was driven by growth in self-injection devices for obesity and diabetes, partially offset by a continued decrease in sales of healthcare diagnostic devices. Contract Manufacturing accounted for 18% of total company net sales in the quarter.Introducing Full-Year and First-Quarter 2026 Financial GuidanceFull-year 2026 net sales are expected to be in a range of $3.215 billion to $3.275 billion, which assumes a mid-year 2026 close for the sale of SmartDose 3.5ml to AbbVie.Reported growth is expected to be between 4.6% and 6.5% while organic net sales growth is expected to be approximately 5% to 7%.Net sales guidance includes an estimated full-year 2026 benefit of 2 percentage points based on current foreign currency exchange rates.SmartDose® 3.5mL generated $55 million in revenues in the second half of 2025. These revenues are excluded to calculate our full-year 2026 organic revenue growth guidance.Full-year 2026 adjusted-diluted EPS is expected to be in a range of $7.85 to $8.20, representing growth of 7.7% to 12.5%.Full-year 2026 capital expenditures are expected to be in the range of $250 million to $275 million.First-quarter 2026 net sales are expected to be in the range of $770 million to $790 million, representing reported growth of 10.3% to 13.2% and organic growth of 4.6% to 7.4%.First-quarter adjusted-diluted EPS is expected to be in the range of $1.65 to $1.70, up 13.0% to 16.4%.Fourth-Quarter and Full-Year 2025 Conference Call
Management will host a conference call at 8 a.m. EDT today. The live webcast can be accessed in the "Investors" section of the Company's website and by clicking here.To participate in the Q&A portion of the conference call, please register in advance by clicking here.Registered telephone participants will receive the dial-in number along with a unique PIN number that will enable them to ask questions on the call.An accompanying slide presentation will be posted in the "Investors" section of the Company's website.A replay of the webcast will be available on the Company's website for approximately 90 days after the event.About West
West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug developers, West helps ensure the safe, effective containment and delivery of life-saving and life-enhancing medicines for patients. With over 10,000 team members across 50 sites including 25 manufacturing facilities worldwide, West helps support our customers by delivering over 41 billion components and devices each year. Headquartered in Exton, Pennsylvania, West in its fiscal year 2025 generated $3.07 billion in net sales. West is traded on the New York Stock Exchange (NYSE: WST) and is included in the Standard & Poor's 500 index. For more information, visit www.westpharma.com. All trademarks and registered trademarks used in this release are the property of West Pharmaceutical Services, Inc. or its subsidiaries, in the United States and other jurisdictions, unless otherwise noted.Daikyo®, Daikyo Crystal Zenith® and Daikyo CZ® are registered trademarks of Daikyo Seiko, Ltd. Daikyo Crystal Zenith technologies are licensed from Daikyo Seiko, Ltd.Forward-Looking Statements
This release contains statements that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may include such words as "expected," "assumes," "unchanged," "includes," "would," "provide" and other similar terminology. These statements reflect management's current expectations regarding future events and operating performance and speak only as of the date of this release. There is no certainty that actual results will be achieved in-line with current expectations. These forward-looking statements involve a number of risks and uncertainties. The following are some of the factors that could cause our actual results to differ materially from those expressed in or underlying our forward-looking statements: prevailing economic conditions and general uncertainties relating thereto that may be unknown and unforeseeable; customers' changing inventory requirements and manufacturing plans and customer decisions to move forward with our new products and product categories; disruptions or limitations in the Company's manufacturing capacity; average profitability, or mix, of the products we sell; dependence on third-party suppliers and partners; increased raw material, energy and labor costs; fluctuations in currency exchange; the ability to meet development milestones with key customers; and the consequences of other geopolitical events, including natural disasters, acts of war, and global health crises. This list of important factors is not all inclusive. For a description of certain additional factors that could cause the Company's future results to differ from those expressed in any such forward-looking statements, see Part I Item 1A, entitled "Risk Factors," in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, and other filings with the United States Securities and Exchange Commission, including the Company's quarterly reports on Form 10-Q and current reports on Form 8-K.Except as required by law or regulation, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.Non-U.S. GAAP Financial Measures
This release contains certain financial measures outside of generally accepted accounting principles ("U.S. GAAP"), including organic net sales and adjusted-diluted EPS. For the purpose of aiding the comparison of our year-over-year results, we may refer to net sales and other financial results excluding the effects of changes in foreign currency exchange rates. Organic net sales exclude the impact from acquisitions and/or divestitures and translate the current-period reported sales of subsidiaries whose functional currency is other than the U.S. Dollar at the applicable foreign currency exchange rates in effect during the comparable prior-year period. We may also refer to financial results excluding the effects of unallocated items. The re-measured results excluding effects from currency translation and excluding the effects of unallocated items are not in conformity with U.S. GAAP and should not be used as a substitute for the comparable U.S. GAAP financial measures. The non-U.S. GAAP financial measures are incorporated into our discussion and analysis as management uses them in evaluating our results of operations and believes that this information provides users a valuable insight into our overall performance and financial position. A reconciliation of these adjusted non-U.S. GAAP measures to the comparable U.S. GAAP financial measures is included in the accompanying tables.WEST PHARMACEUTICAL SERVICES, INC.CONSOLIDATED STATEMENTS OF INCOME(UNAUDITED)(in millions, except per share data)

Three Months Ended
December 31,
Twelve Months Ended
December 31,
2025
2024
2025
2024Net sales$     805.0
100 %
$     748.8
100 %
$ 3,074.1
100 %
$ 2,893.2
100 %Cost of goods and services sold501.1
62
475.2
63
1,970.1
64
1,894.7
65Gross profit303.9
38
273.6
37
1,104.0
36
998.5
35Research and development21.8
3
18.5
3
74.3
2
69.1
2Selling, general and administrative
expenses107.0
14
85.3
12
393.6
13
338.5
12Other expense (income), net18.5
2
10.2
1
51.2
2
21.0
1Operating profit156.6
19
159.6
21
584.9
19
569.9
20Interest (income) expense, net(5.3)
(1)
(5.6)
(1)
(17.0)
(1)
(16.6)
—Other nonoperating expense
(income)0.4
—
0.3
—
1.0
—
1.0
—Income before income taxes and
equity in net income of affiliated
companies161.5
20
164.9
22
600.9
20
585.5
20Income tax expense33.3
4
36.8
4
121.6
4
107.5
4Equity in net income of affiliated
companies(3.9)
—
(2.0)
—
(14.4)
—
(14.7)
(1)Net income$     132.1
16 %
$     130.1
18 %
$     493.7
16 %
$     492.7
17 %

Net income per share:

Basic$       1.83

$       1.79

$       6.83

$       6.75

Diluted$       1.82

$       1.78

$       6.79

$       6.69

Average common shares
outstanding72.3

72.7

72.3

73.0

Average shares assuming dilution72.7

73.3

72.7

73.7

WEST PHARMACEUTICAL SERVICESREPORTING SEGMENT INFORMATION(UNAUDITED)(in millions)

Three Months EndedDecember 31,
Twelve Months EndedDecember 31,Net Sales:2025
2024
2025
2024Proprietary Products$          661.8
$          613.9
$       2,492.1
$       2,334.5Contract-Manufactured Products143.2
134.9
582.0
558.7Consolidated Total$          805.0
$          748.8
$       3,074.1
$       2,893.2

Gross Profit:

Proprietary Products$          285.7
$          250.7
$       1,008.2
$          900.5Contract-Manufactured Products18.2
22.9
95.8
98.0Gross Profit$          303.9
$          273.6
$       1,104.0
$          998.5Gross Profit Margin37.8 %
36.5 %
35.9 %
34.5 %

Operating Profit (Loss):

Proprietary Products$          189.7
$          162.3
$          657.2
$          577.8Contract-Manufactured Products9.8
16.2
63.4
72.3Stock-based compensation expense(6.7)
(4.3)
(23.8)
(18.7)General corporate costs(36.2)
(14.6)
(111.9)
(61.5)Reported Operating Profit$          156.6
$          159.6
$          584.9
$          569.9Reported Operating Profit Margin19.5 %
21.3 %
19.0 %
19.7 %

Unallocated items15.4
3.2
37.5
2.9Adjusted Operating Profit$          172.0
$          162.8
$          622.4
$          572.8Adjusted Operating Profit Margin21.4 %
21.7 %
20.2 %
19.8 % WEST PHARMACEUTICAL SERVICESRECONCILIATION OF NON-U.S. GAAP MEASURES (UNAUDITED)Please refer to "Non-U.S. GAAP Financial Measures" for more information(in millions, except per share data)
Reconciliation of Reported and Adjusted Operating Profit, Net Income and Diluted EPSThree Months ended December 31, 2025Operatingprofit
Incometaxexpense
Netincome
DilutedEPSReported (U.S. GAAP)$156.6
$33.3
$132.1
$1.82Unallocated items:

Restructuring and other charges (1)1.4
(2.1)
3.4
0.05SmartDose® 3.5mL sale (2)8.4
1.9
6.5
0.09Cost-method investment activity (3)4.5
—
4.5
0.06Amortization of acquisition-related intangible assets (4)—
—
0.5
0.01Other1.1
0.3
0.8
0.01Adjusted (Non-U.S. GAAP)$172.0
$33.4
$147.8
$2.04
Twelve Months ended December 31, 2025Operatingprofit
Incometaxexpense
Netincome
DilutedEPSReported (U.S. GAAP)$584.9
$121.6
$493.7
$6.79Unallocated items:

Restructuring and other charges (1)23.3
0.9
22.4
0.31SmartDose® 3.5mL sale (2)8.4
1.9
6.5
0.09Cost-method investment activity (3)4.5
—
4.5
0.06Amortization of acquisition-related intangible assets (4)0.2
—
2.0
0.03Other1.1
0.3
0.8
0.01Adjusted (Non-U.S. GAAP)$622.4
$124.7
$529.9
$7.29
Three Months ended December 31, 2024Operatingprofit
Incometaxexpense
Netincome
DilutedEPSReported (U.S. GAAP)$159.6
$36.8
$130.1
$1.78Unallocated items:

Restructuring and other charges (1)3.0
0.7
2.3
0.03Amortization of acquisition-related intangible assets (4)0.2
—
0.7
0.01Adjusted (Non-U.S. GAAP)$162.8
$37.5
$133.1
$1.82
Twelve Months ended December 31, 2024Operatingprofit
Incometaxexpense
Netincome
DilutedEPSReported (U.S. GAAP)$569.9
$107.5
$492.7
$6.69Unallocated items:

Restructuring and other charges (1)2.1
0.4
1.7
0.02Amortization of acquisition-related intangible assets (4)0.8
0.1
2.8
0.04Adjusted (Non-U.S. GAAP)$572.8
$108.0
$497.2
$6.75

(1)During the three and twelve months ended December 31, 2025, the Company recorded pre-tax charges of $1.4 million and $23.3 million, respectively, related to our two existing restructuring programs: (i) 0.9 million and $18.4 million in the three and twelve months ended December 31, 2025, respectively, within other expense (income), related to severance, acceleration of depreciation and lease costs in connection with the Company's January 2025 restructuring plan and (ii) $0.5 million and $4.9 million in the three and twelve months ended December 31, 2025, respectively, within selling, general and administrative expenses, for professional services relating to our 2024 plan to optimize the legal structure of the Company and its subsidiaries. In addition, we recorded income tax charges of $2.3 million and $4.9 million during the three and twelve months ended December 31, 2025, respectively, related primarily to withholding tax and capital gains incurred in executing our plan to optimize our legal structure. During the three and twelve months ended December 31, 2024, the Company recorded expense to restructuring and other charges of $3.0 million and $2.1 million, respectively. The net expense represents the impact of two items, the first of which is an expense $3.0 million and $4.6 million during the three and twelve months ended December 31, 2024, respectively, recorded within selling, general and administrative expenses in connection with a plan to optimize the legal structure of the Company and its subsidiaries. The expense consisted primarily of consulting fees, legal expenses, and other one-time costs directly attributable to this plan. This expense was partially offset by a $2.5 million benefit in the twelve months ended December 31, 2024 recorded within other expense (income) related to revised severance estimates in connection with the Company's 2022 restructuring plan.(2)During the three and twelve months ended December 31, 2025, the Company recorded charges of $8.4 million related to the Company's agreement to sell its SmartDose® 3.5mL On-Body Delivery System and associated facilities to AbbVie. The Company recorded $6.2 million of the charges within other expense (income), related to severance and lease impairment charges in connection with the sale agreement. The Company recorded the remaining $2.2 million within selling, general and administrative expenses, relating to professional services in connection with the sale agreement.(3)During the three and twelve months ended December 31, 2025, the Company recorded cost-method investment impairment charges of $4.5 million within other expense (income).(4)During the three and twelve months ended December 31, 2025 and 2024, the Company recorded $0.0 million and $0.2 million, and $0.2 million and $0.8 million, respectively, of amortization expense within operating profit associated with an intangible asset acquired during the second quarter of 2020. During the three and twelve months ended December 31, 2025 and 2024, the Company recorded $0.5 million and $1.8 million, and $0.5 million and $2.1 million, respectively, of amortization expense in association with an acquisition of increased ownership interest in Daikyo. WEST PHARMACEUTICAL SERVICESRECONCILIATION OF NON-U.S. GAAP FINANCIAL MEASURES (UNAUDITED)Please refer to "Non-U.S. GAAP Financial Measures" for more information(in millions, except per share data)
Reconciliation of Reported Net Sales to Organic Net Sales by Segment(5)
Three Months ended December 31,Reported Net Sales (U.S.
GAAP)
Percent
Change
Impact of
CurrencyOrganic Net Sales
Growth Rate (Decline)
(Non-U.S. GAAP) (5)20252024

Proprietary Products$661.8$613.9
7.8 %
4.2 %3.6 %Contract-Manufactured Products143.2134.9
6.2 %
4.3 %1.9 %Total$805.0$748.8
7.5 %
4.2 %3.3 %
Twelve Months ended December 31,Reported Net Sales (U.S.
GAAP)
Percent
Change
Impact of
CurrencyOrganic Net Sales
Growth Rate (Decline)
(Non-U.S. GAAP) (5)20252024

Proprietary Products$2,492.1$2,334.5
6.8 %
2.0 %4.8 %Contract-Manufactured Products582.0558.7
4.2 %
2.1 %2.1 %Total$3,074.1$2,893.2
6.3 %
2.0 %4.3 % Reconciliation of Proprietary Products Segment Organic Net Sales by Product Category(5)
Three Months ended December 31,Reported Net Sales (U.S.
GAAP)
Percent
Change
Impact of
CurrencyOrganic Net Sales
Growth Rate (Decline)
(Non-U.S. GAAP) (5)20252024

HVP Components$389.8$324.1
20.3 %
5.2 %15.1 %HVP Delivery Devices110.4132.9
(16.9) %
1.2 %(18.1) %Standard Products161.6156.9
3.0 %
4.7 %(1.7) %Total Proprietary Products$661.8$613.9
7.8 %
4.2 %3.6 %
Twelve Months ended December 31,Reported Net Sales (U.S.
GAAP)
Percent
Change
Impact of
CurrencyOrganic Net Sales
Growth Rate (Decline)
(Non-U.S. GAAP) (5)20252024

HVP Components$1,451.0$1,305.0
11.2 %
2.3 %8.9 %HVP Delivery Devices406.4404.5
0.5 %
0.8 %(0.3) %Standard Products634.7625.0
1.6 %
1.9 %(0.3) %Total Proprietary Products$2,492.1$2,334.5
6.8 %
2.0 %4.8 % Reconciliation of Proprietary Products Segment Organic Net Sales by Market Group(5)
Three Months ended December 31,Reported Net Sales (U.S.
GAAP)
Percent
Change
Impact of
CurrencyOrganic Net Sales
Growth Rate (Decline)
(Non-U.S. GAAP) (5)20252024

Biologics$340.4$305.2
11.5 %
4.2 %7.3 %Pharma191.5181.6
5.5 %
5.2 %0.3 %Generics129.9127.1
2.2 %
2.8 %(0.6) %Total Proprietary Products$661.8$613.9
7.8 %
4.2 %3.6 %
Twelve Months ended December 31,Reported Net Sales (U.S.
GAAP)
Percent
Change
Impact of
CurrencyOrganic Net Sales
Growth Rate (Decline)
(Non-U.S. GAAP) (5)20252024

Biologics$1,226.5$1,116.6
9.8 %
2.1 %7.7 %Pharma753.1712.4
5.7 %
2.3 %3.4 %Generics512.5505.5
1.4 %
0.8 %0.6 %Total Proprietary Products$2,492.1$2,334.5
6.8 %
2.0 %4.8 % Reconciliation of Reported Net Sales to Organic Net Sales by Geography(5)
Three Months ended December 31,Reported Net Sales (U.S.
GAAP)
Percent
Change
Impact of
CurrencyOrganic Net Sales
Growth Rate (Decline)
(Non-U.S. GAAP) (5)20252024

Americas$358.6$354.8
1.1 %
0.4 %0.7 %Europe, Middle East, Africa370.2323.0
14.6 %
9.5 %5.1 %Asia Pacific76.271.0
7.3 %
(1.0) %8.3 %Total$805.0$748.8
7.5 %
4.2 %3.3 %
Twelve Months ended December 31,Reported Net Sales (U.S.
GAAP)
Percent
Change
Impact of
CurrencyOrganic Net Sales
Growth Rate (Decline)
(Non-U.S. GAAP) (5)20252024

Americas$1,422.5$1,311.9
8.4 %
(0.2) %8.6 %Europe, Middle East, Africa1,387.91,323.5
4.9 %
4.7 %0.2 %Asia Pacific263.7257.8
2.3 %
(1.5) %3.8 %Total$3,074.1$2,893.2
6.3 %
2.0 %4.3 %

(5)Organic net sales exclude the impact from acquisitions and/or divestitures and translate the current-period reported sales of subsidiaries whose functional currency is other than the U.S. Dollar at the applicable foreign currency exchange rates in effect during the comparable prior-year period. WEST PHARMACEUTICAL SERVICESRECONCILIATION OF NON-U.S. GAAP FINANCIAL MEASURES (UNAUDITED)Please refer to "Non-U.S. GAAP Financial Measures" for more information(in millions, except per share data)
Reconciliation of Reported-Diluted EPS Guidance to Adjusted-Diluted EPS Guidance
2025 Actual
2026 Guidance
% ChangeReported-diluted EPS (U.S. GAAP)$6.79
$7.79 to $8.14
14.7% to 19.9%Restructuring and other charges0.31
0.04

SmartDose® 3.5mL sale0.09
—

Cost-method investment activity0.06
—

Amortization of acquisition-related intangible assets0.03
0.02

Other0.01
—

Adjusted-diluted EPS (Non-U.S. GAAP)$7.29
$7.85 to $8.20
7.7% to 12.5%
Notes: See "Introducing Full-Year and First-Quarter 2026 Financial Guidance" and "Non-U.S. GAAP Financial Measures" in today's press release for additional information regarding adjusted-diluted EPS. WEST PHARMACEUTICAL SERVICESCONSOLIDATED BALANCE SHEETS
(in millions, except per share data)2025
2024ASSETS

Current assets:

Cash and cash equivalents$            791.3
$            484.6Accounts receivable, net574.4
552.5Inventories443.9
377.0Other current assets168.6
124.0Total current assets1,978.2
1,538.1Property, plant and equipment3,223.4
2,985.8Less: accumulated depreciation and amortization1,497.0
1,404.2Property, plant and equipment, net1,726.4
1,581.6Operating lease right-of-use assets117.0
104.5Investments in affiliated companies212.3
202.1Goodwill109.9
106.0Intangible assets, net7.7
10.8Deferred income taxes38.4
26.0Other noncurrent assets80.1
74.3Total Assets$         4,270.0
$         3,643.4

LIABILITIES AND EQUITY

Current liabilities:

Accounts payable253.7
239.3Accrued salaries, wages and benefits135.9
73.5Income taxes payable28.1
31.5Operating lease liabilities22.7
17.9Other current liabilities214.5
188.2Total current liabilities654.9
550.4Long-term debt202.8
202.6Deferred income taxes23.0
20.5Pension and other postretirement benefits29.0
28.2Operating lease liabilities95.6
81.8Deferred compensation benefits13.5
15.4Other long-term liabilities75.2
62.2Total Liabilities1,094.0
961.1

Commitments and contingencies (Note 18)

Equity:

Preferred stock, 3.0 million shares authorized; 0.0 shares issued and
outstanding in 2025 and 2024—
—Common stock, par value $0.25 per share; 200 million shares authorized;
shares issued: 75.3 million in 2025 and 2024; shares outstanding: 72.0 million
and 72.3 million in 2025 and 202418.8
18.8Capital in excess of par value—
22.1Retained earnings4,374.9
3,956.6Accumulated other comprehensive loss(105.5)
(258.1)Treasury stock, at cost (3.3 million and 3.0 million shares in 2025 and 2024)(1,112.2)
(1,057.1)Total Equity3,176.0
2,682.3Total Liabilities and Equity$         4,270.0
$         3,643.4 WEST PHARMACEUTICAL SERVICESCONSOLIDATED STATEMENTS OF CASH FLOWS(in millions)

Twelve Months Ended
December 31,
2025
2024Cash flows from operating activities:

Net income$              493.7
$              492.7Adjustments to reconcile net income to net cash provided by operating activities:

Depreciation168.6
151.8Amortization2.8
3.6Stock-based compensation23.8
18.7Non-cash restructuring charges5.4
—Asset impairments11.7
7.3Deferred income taxes(13.7)
(3.5)Pension and other retirement plans, net0.6
(2.0)Equity in undistributed earnings of affiliates, net of dividends(10.5)
(13.4)Other, net(7.4)
(4.7)Changes in assets and liabilities:

Decrease (increase) in accounts receivable6.9
(58.8)(Increase) decrease in inventories(62.8)
42.0(Increase) decrease in other current assets9.7
(5.8)Increase in accounts payable17.9
2.9Changes in other assets and liabilities108.1
22.6Net cash provided by operating activities754.8
653.4Cash flows from investing activities:

Capital expenditures(285.9)
(377.0)Other, net—
(1.7)Net cash used in investing activities(285.9)
(378.7)Cash flows from financing activities:

Borrowings of long-term debt—
164.7Repayments of long-term debt—
(169.0)Principal repayments on finance leases(1.1)
(23.3)Dividend payments(61.2)
(59.1)Excise tax payments(4.2)
(2.0)Proceeds from stock-based compensation awards11.3
25.5Employee stock purchase plan contributions6.9
7.2Shares purchased under share repurchase programs(134.0)
(560.9)Shares repurchased for employee tax withholdings(2.8)
(5.7)Net cash used in financing activities(185.1)
(622.6)Effect of exchange rates on cash22.9
(21.4)Net increase (decrease) in cash and cash equivalents306.7
(369.3)Cash, including cash equivalents at beginning of period484.6
853.9Cash, including cash equivalents at end of period$              791.3
$              484.6

Supplemental cash flow information:

Interest paid, net of amounts capitalized$                  0.3
$                  0.5Income taxes paid, net$              125.2
$                71.4Accrued capital expenditures$                37.9
$                53.0Dividends declared, not paid$                15.8
$                15.2

View original content to download multimedia:https://www.prnewswire.com/news-releases/west-reports-fourth-quarter-and-full-year-2025-results-302685827.htmlSOURCE West Pharmaceutical Services, Inc.

Original: West Reports Fourth-Quarter and Full-Year 2025 Results